Testing an ultrasound device with chemotherapy for glioblastoma that has come back
Original title: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage trial in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether opening the brain's natural shield with sound waves helps a chemo drug reach a glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back.
Who this trial is for. This trial is for people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has come back. It compares the SonoCloud-9 device plus the chemotherapy drug carboplatin against the usual chemotherapy drugs, CCNU or TMZ.
Where it stands. This trial has not reported results. It is testing whether carboplatin works better when the SonoCloud-9 device is used to open the blood-brain barrier first. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Blood vessels in the brain block most drugs from getting to a tumor. This device is meant to open that block for a short time so more of the drug can reach the tumor. Someone who thinks they might fit can ask their care team about it.
What it doesn't mean: This does not mean the approach works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.